Literature DB >> 19151123

Influences on bone mineral density in Malaysian premenopausal systemic lupus erythematosus patients on corticosteroids.

S S Yeap1, A R Fauzi, N C T Kong, A G Halim, Z Soehardy, S Rahimah, S K Chow, E M L Goh.   

Abstract

The aim of this study was to assess the bone mineral density (BMD) of premenopausal patients with systemic lupus erythematosus (SLE) on corticosteroids (CS) and to determine the influence of CS and other risk factors on BMD. A total of 98 premenopausal patients with SLE were recruited from outpatient clinics in two teaching hospitals. Risk factors for osteoporosis were determined, and BMD was measured using dual-energy x-ray absorptiometry. The mean age of the patients was 30.05 +/- 7.54 years. The mean dose of prednisolone at time of BMD measurement was 18.38 +/- 10.85 mg daily. Median duration of CS use was 2.5 years (range 0-20). Median cumulative dose of CS was 9.04 g (range 0.28-890.0). Six patients (6.1%) had osteoporosis, 41 (41.9%) had osteopenia and 51 (52.0%) had normal BMD. Lumbar spine T score correlated with cumulative CS dose (P = 0.019). Duration of CS intake correlated with femoral neck T score (P = 0.04) and trochanter T score (P = 0.008). There was no correlation between BMD and race, SLE Disease Activity Index score, smoking and self-reported calcium intake or exercise. Only 52% of these patients had normal BMD. The duration and cumulative dose of CS intake was significantly correlated to BMD, but not the other commonly assessed risk factors. These findings suggest that premenopausal patients with SLE on CS should have their BMD measured at regular intervals to fully assess their osteoporosis risk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19151123     DOI: 10.1177/0961203308094995

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Lower P1NP serum levels: a predictive marker of bone loss after 1 year follow-up in premenopausal systemic lupus erythematosus patients.

Authors:  L P C Seguro; C B Casella; V F Caparbo; R M Oliveira; A Bonfa; E Bonfa; R M R Pereira
Journal:  Osteoporos Int       Date:  2014-08-22       Impact factor: 4.507

2.  Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only.

Authors:  C-C Lai; W-S Chen; D-M Chang; Y-P Tsao; T-H Wu; C-T Chou; C-Y Tsai
Journal:  Osteoporos Int       Date:  2014-10-01       Impact factor: 4.507

3.  High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis.

Authors:  Danieli Castro Oliveira de Andrade; Sonia Cristina de Magalhães Souza; Jozélio Freire de Carvalho; Liliam Takayama; Claudia Teresa Lobato Borges; José Mendes Aldrighi; Rosa Maria Rodrigues Pereira
Journal:  Rheumatol Int       Date:  2011-02-16       Impact factor: 2.631

4.  RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.

Authors:  A C Bonfá; L P C Seguro; V Caparbo; E Bonfá; R M R Pereira
Journal:  Osteoporos Int       Date:  2015-01-22       Impact factor: 4.507

Review 5.  Glucocorticoid-induced osteoporosis in rheumatic diseases.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ernesto Canalis
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

6.  Common Variants in OPG Confer Risk to Bone Mineral Density Variation and Osteoporosis Fractures.

Authors:  Xiaoyong Sheng; Guangyong Cai; Xingjun Gong; Zouying Yao; Ye Zhu
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.